Business Context and Reporting Period
This Form 8-K was filed by Coherus BioSciences, Inc. (CHRS) on July 18, 2023. The report discloses a corporate governance event: the appointment of a new member to the Board of Directors.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
The primary material change reported is the appointment of Michael Ryan, Pharm.D., as a Class III director to fill a vacancy on the Board. Dr. Ryan brings four decades of experience in academia and the biopharmaceutical industry, including senior roles at Bristol-Myers Squibb and Amgen.
Guidance, Outlook, and Compensation Details
There is no financial guidance, outlook, or management commentary regarding business operations in this filing. The document details the following compensatory arrangements for Dr. Ryan:
- Term: Service until the 2026 annual meeting of stockholders or until a successor is elected.
- Cash Retainer: An annual cash retainer of $50,000.
- Equity Award: An option to purchase 54,000 shares of common stock at the closing price on the appointment date.
- Vesting: The option vests in substantially equal monthly installments over three years, contingent on continued service.
- Indemnification: Dr. Ryan will receive a standard director and officer indemnification agreement.
Investor Verification Checklist
- Verify the total number of outstanding shares and the impact of the 54,000 new options on potential dilution.
- Review the Company's 2014 Equity Incentive Award Plan to confirm the availability of shares for this grant.
- Confirm the vesting schedule and any acceleration clauses in the option agreement.
- Check for any related party transactions or conflicts of interest involving Dr. Ryan's current role at Koios Enterprises & Consulting.